Medicare Coverage for ALS: 2025 Guide

ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease) is one of only two conditions — along with End-Stage Renal Disease — that qualifies Americans for Medicare regardless of age, immediately upon receiving Social Security Disability Insurance (SSDI) approval. There is no 24-month waiting period. This is one of the most important Medicare provisions for ALS patients and families to understand.

ALS Coverage Quick Reference

Immediate Medicare Eligibility: The ALS Exception

Understanding how ALS patients qualify for Medicare is essential:

• Normal SSDI pathway: Most disability beneficiaries must wait 24 months after their first SSDI payment before Medicare coverage begins
• ALS exception: Medicare begins in the same month as the first SSDI payment — no waiting period whatsoever
• Why it matters: ALS progresses rapidly. Many patients progress from diagnosis to significant disability within 2–3 years. A 24-month Medicare wait would leave newly disabled ALS patients without Medicare coverage during the period they most need it
• SSDI filing: File for SSDI as soon as possible after ALS diagnosis — the five-month SSDI waiting period (before first payment) still applies, but there is no additional Medicare delay beyond that

Once on Medicare, ALS patients under 65 are enrolled in the same Medicare program as beneficiaries over 65 — with the same benefits, coverage rules, and Medigap eligibility.

ALS Medications Covered Under Medicare

Medicare Part D covers FDA-approved ALS disease-modifying medications:

Riluzole (Rilutek, Tiglutik, Exservan)

Riluzole was the first FDA-approved treatment for ALS (1995). It modestly extends survival (by approximately 2–3 months on average) and is standard of care. Generic riluzole is now available and covered under Part D at Tier 1–2. Brand oral suspension formulations (Tiglutik) and oral film formulations (Exservan) are higher tiers but still subject to the $2,000 annual OOP cap. Prior authorization may be required for brand formulations.

Edaravone (Radicava, Radicava ORS)

Edaravone received FDA approval in 2017 (IV formulation) and 2022 (oral formulation). Coverage depends on formulation:

• IV edaravone (Radicava): Physician-administered infusion, covered under Part B at 20% coinsurance. The drug alone costs approximately $145,000/year list price — 20% without Medigap is $29,000. Medigap Plan G covers the 20%.
• Oral edaravone (Radicava ORS): Self-administered, covered under Part D. Subject to the $2,000 annual out-of-pocket cap — a dramatic improvement over prior years.

Note on AMX0035 (Relyvrio)

AMX0035 (sodium phenylbutyrate/ursodoxicoltaurine) received accelerated FDA approval in September 2022 but was withdrawn from the US market in April 2024 after a confirmatory Phase 3 trial (PHOENIX) failed to show benefit. It is no longer available.

Respiratory Equipment: BiPAP and Ventilation

Respiratory failure is the leading cause of death in ALS. Medicare covers the equipment needed to manage respiratory compromise:

BiPAP / Noninvasive Ventilation (NIV)

Medicare Part B covers a respiratory assist device (RAD/BiPAP) when:

• FVC (forced vital capacity) is less than 50% of predicted, OR
• There are symptoms of respiratory muscle weakness (orthopnea, nocturnal hypoventilation) even with FVC above 50%

ALS patients often qualify earlier than other conditions because respiratory failure is predictable. Your pulmonologist or neurologist should document qualifying criteria carefully. BiPAP is covered as DME — you pay 20% of the rental cost, and Medicare transitions to ownership after 13 months of rental.

Mechanical In-Exsufflator (Cough Assist)

The CoughAssist device helps clear secretions when cough muscles weaken. Covered under Part B when respiratory muscle weakness is documented. Particularly important as dysphagia increases aspiration risk.

Invasive Ventilation

If ALS patients choose tracheostomy and invasive mechanical ventilation (a decision requiring careful family discussion), the ventilator is covered as DME for home use under Part B. Home nursing or respiratory therapy to manage the ventilator is covered under the home health benefit if skilled care criteria are met.

Nutrition: PEG Tubes and Enteral Nutrition

Dysphagia (difficulty swallowing) affects most ALS patients and creates serious nutritional risk. Medicare covers:

• PEG tube placement procedure: Covered under Part B (outpatient) or Part A (if inpatient stay required)
• Enteral nutrition (tube feeding formula): Covered under Part B as a prosthetic device when the alimentary (gastrointestinal) canal is non-functional or when oral intake is insufficient to maintain adequate nutrition. ALS with dysphagia qualifies. You pay 20% of the approved amount for formula, pump, and supplies.

Timing matters: the ALS Association recommends PEG placement while FVC is still above 50%, as the procedure becomes higher risk with significant respiratory impairment.

Power Wheelchairs and Mobility Equipment

ALS causes progressive limb weakness requiring early attention to mobility equipment. Medicare Part B covers:

• Power wheelchair (PWC): For patients who cannot self-propel a manual wheelchair due to upper and/or lower extremity weakness. ALS patients typically qualify for a Group 3 power wheelchair, which provides full power seating adjustments (tilt, recline, leg elevation) important for pressure injury prevention. Requires: face-to-face physician/NP evaluation, 7-element order, and in-home assessment by a certified ATP (assistive technology professional).
• Manual wheelchair: For early-stage patients who still have sufficient upper extremity strength
• Power seat functions: Tilt-in-space, power recline, and power leg rests are covered separately when medically necessary and documented
• Hospital bed, patient lift (Hoyer): Covered as DME for home use as disease progresses

Start the mobility equipment process early. Medicare documentation requirements and prior authorization for power wheelchairs can take weeks, and having the equipment in place before it becomes urgently needed is important.

Augmentative & Alternative Communication (AAC) Devices

Medicare covers speech-generating devices (SGDs) — including sophisticated eye-tracking AAC systems used in late-stage ALS — as durable medical equipment under Part B:

• Coverage trigger: When the patient can no longer meet daily communication needs through natural speech
• Documentation required: Speech-language pathologist (SLP) evaluation documenting communication impairment, trial of lower-tech alternatives, and selection rationale
• Device types covered: Dedicated speech-generating devices (not general-purpose tablets/computers); eye-tracking systems (like Tobii Dynavox) are covered as dedicated SGDs
• Cost: 20% of Medicare-approved amount; high-end eye-tracking AAC systems can cost $8,000–$15,000, so Medigap coverage (paying the 20%) is valuable

Introduce AAC early — the ALS Association recommends beginning AAC evaluation when speech intelligibility drops below 90%, not waiting for complete loss of speech. Familiarity with the device before urgent need improves outcomes.

Home Health and Therapy Services

Medicare covers home health services for ALS patients who are homebound and require skilled care:

• Skilled nursing: Wound care, medication management, teaching patient/caregiver techniques
• Physical therapy: Strength maintenance, fall prevention, mobility training, equipment training
• Occupational therapy: Adaptive equipment, energy conservation, home modification recommendations, ADL strategies
• Speech-language pathology: Dysphagia management, AAC training, communication strategies

There is no limit on the number of home health visits as long as the patient remains homebound and requires skilled care. ALS patients often meet homebound criteria once ambulation becomes significantly impaired. Home health visits are covered at $0 — no coinsurance.

Hospice Care for ALS

When ALS patients elect hospice, Medicare Part A covers comprehensive end-of-life care:

• All care related to the terminal diagnosis (ALS) is covered, including ventilator support if the patient is on a home ventilator
• Medications related to ALS comfort and symptom management are covered at minimal cost
• 24/7 nursing support and crisis care
• Social work, chaplaincy, and bereavement support for family
• Respite care (short inpatient stays to give caregivers a break) — up to 5 consecutive days

ALS patients and families should understand that electing hospice does not require discontinuing the home ventilator or other equipment already in place. Hospice physicians have experience managing ALS patients on ventilators.

The Custodial Care Gap

The most significant coverage gap for ALS patients is custodial care — the 24-hour supervision, assistance with bathing, dressing, feeding, repositioning, and caregiving that becomes necessary as ALS progresses. Medicare does NOT cover custodial care. This is the primary financial burden for ALS families:

• Home health aides are not covered unless there is also skilled care (nursing/therapy) being provided
• When the skilled care episode ends, home health aides must also stop under Medicare
• 24-hour home care for late-stage ALS can cost $15,000–$25,000/month
• Nursing facility custodial care costs $8,000–$12,000/month

Medicaid can cover custodial care for ALS patients who meet income/asset limits. The ALS Association's chapter network provides navigation assistance for families facing this gap. Some states have Medicaid waiver programs specifically for home and community-based care that can help ALS patients remain at home longer.

Frequently Asked Questions